An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
Clinical trial NCT05741528 · COMPLETED
Trial details
- NCT number
- NCT05741528
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-31
- Primary completion
- 2024-09-23
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.